Impaired supersensitivity to morphine following chronic naltrexone treatment in senescent rats

Ontogeny of the pain

The article gives an overview of developmental aspects of the ontogeny of pain both in experimental models and in children. The whole article is devoted to the ontogenesis in pain perception and the possible influence on it. The role of endogenous opioids on the development of pain and other important substances such as serotonin, nerve growth factor (NGF) and nicotine are mentioned. There are also important differences of the ontogenesis of thermal and mechanical nociceptive stimulation. The physiological and pathophysiological findings are the backgrounds for principles of treatment, taking into account the special status of analgesics during ontogeny. In particular there are mentioned the special effects of endogenous opioids and especially morphine. It describes the role of vitamin D and erythropoietin during the development of pain perception. This article also mentioned the critical developmental periods in relation to the perception of pain. The attention is paid to stress and immunological changes during the ontogeny of pain. Another important role is played by microglia. The work is concluded by some statements about the use of physiological and pathophysiological findings during the treatment of pain in pediatric practice. Codein analgesia is also described because codein starts to be very modern drug with the dependence.

Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence

Naltrexone, an opioid receptor antagonist, is effective in the treatment of alcohol and opioid dependence. An important limitation of the use of oral naltrexone is the lack of efficacy among patients who do not consistently take the medication. The advent of a sustained-release naltrexone addresses the problem of noncompliance. Naltrexone can be compounded into microcapsules that can be injected or implanted, producing a clinical response lasting from 30 days to several months. Several randomized, placebo-controlled clinical trials demonstrate that sustained-release naltrexone is safe and effective for the treatment of both alcohol and opioid dependence. Sustained-release formulations of naltrexone may offer several advantages over its oral formulation with respect to medication compliance, pharmacokinetics, side effect profile and ease of use. Recently, one formulation of sustained-release naltrexone received approval from the US FDA and offers a new option for addiction treatment.

Opposite effects of acute versus chronic naltrexone administration on ethanol-induced locomotion

Several studies have pointed out that the mu opioid receptor (MOR) can play a key role in some of the behavioural effects of ethanol. In the present study, the implication of the MOR in ethanol-induced locomotion in mice was assessed. First, the effects of the administration of different naltrexone doses (0.001-1.000 mg/kg) on the locomotor changes produced by ethanol (2.5 g/kg) were evaluated. In a second set of experiments, the ability of repeated naltrexone (6 mg/kg) administrations to modify the effects of ethanol was also assessed on mice locomotion. The results of the present study revealed that an acute naltrexone administration reduced dose-dependently ethanol-induced locomotion. Conversely, after repeated naltrexone injections, a transient boost of ethanol induced locomotor activity was observed. Thus, the results of the present study revealed that the effects of these naltrexone pretreatments on ethanol-induced locomotion are similar to the previously described changes on MOR activity. Moreover, the same (acute and chronic) naltrexone pretreatments produced similar changes on the locomotion of mice after a challenge with morphine (a MOR agonist), but not after tert-butanol (an alcohol which does not release beta-endorphins) administration. Therefore, our results are discussed in terms of the proved ability of ethanol to promote the release of beta-endorphins and, consequently, to activate the MOR.

Pain tolerance in opioid addicts on and off naltrexone pharmacotherapy: a pilot study

Under certain experimental and clinical conditions, opioid antagonists have been demonstrated to have analgesic properties. In this open-label, nonrandomized, within-subject comparison, the effect of chronic treatment with the antagonist, naltrexone, on tolerance for experimental pain was evaluated in a small sample of male opioid addicts (N = 10) receiving naltrexone maintenance. Cold-pressor pain tolerance was measured during (> or = 6 weeks) and after discontinuation (> or = 1 week) of naltrexone treatment. Intra-subject comparison revealed that eight of the ten subjects were more pain tolerant (median + 20 sec) while receiving naltrexone. It is suggested that either midbrain opioid system upregulation in the presence of naltrexone or underlying individual differences in pain tolerance in persons with addictive disease provide potential explanations for these findings.

Endogenous opiates: 1994

This article is the 17th installment of our annual review of research concerning the opiate system. It includes papers published during 1994 involving the behavioral, nonanalgesic, effects of the endogenous opiate peptides. The specific topics covered this year include stress; tolerance and dependence; eating; drinking; gastrointestinal, renal, and hepatic function; mental illness and mood; learning, memory, and reward; cardiovascular responses; respiration and thermoregulation; seizures and other neurological disorders; electrical-related activity; general activity and locomotion; sex, pregnancy, and development; immunological responses; and other behaviors.